Amneal Pharmaceuticals has opened a ₹135-crore administrative office in Ahmedabad, which will house 1,200 employees. This facility is part of the company's larger plan to invest up to $200 million in two new manufacturing plants. The move aims to boost production of complex medicines, including peptides, to improve the company's competitive position in the global market.
Amneal Pharmaceuticals has expanded its operational presence in Gujarat by launching a new ₹135-crore administrative office in Ahmedabad. The facility, which covers 3.35 lakh square feet, is designed to serve as a central hub for the company's research, development, and corporate functions. With space for 1,200 employees, the site aims to better coordinate the firm's cross-border teams across India, the United States, and Ireland.
This investment is a step toward the company's larger plan to expand its manufacturing capabilities in India. In late 2024, Amneal outlined a capital spending plan of $150 million to $200 million for the construction of two greenfield manufacturing plants in the same region. These upcoming facilities are intended to produce high-barrier, complex generic medicines, specifically focusing on peptide synthesis and sterile fill-finish products. Moving into these areas is a common strategy for pharmaceutical firms looking to access products with fewer competitors and potentially better profit margins.
Since its entry into the Indian market in 2008, Amneal has invested approximately $600 million to build its local infrastructure. The company now operates a network of eight manufacturing sites across cities such as Ahmedabad, Dahej, Hyderabad, and Visakhapatnam. This infrastructure is vital for the company's goal of growing its presence in the biosimilars and injectables market, a segment it further strengthened through its acquisition of Kashiv BioSciences in August 2026.
While the expansion signals growth, investors often monitor risks associated with moving into complex medicines. Developing products like peptides requires high technical expertise and strict adherence to quality standards. As with any pharmaceutical expansion, the company faces the ongoing risk of regulatory scrutiny from bodies like the US Food and Drug Administration (USFDA). Any delay in commissioning these new plants or issues with quality control could affect the projected growth. The primary monitorable for the coming quarters will be the construction progress of the new greenfield plants and whether the company can successfully bring these complex products to market on schedule.